viewPressure BioSciences, Inc.

Pressure BioSciences says Cannaworx in potential deal to acquire Five Leaf Labs in Louisiana

The move will lead to major expansion of the group’s sales and distribution network

Pressure BioSciences, Inc. - Pressure BioSciences says Cannaworx in potential deal to acquire Five Leaf Labs in Louisiana
The strategic acquisition gives Cannaworx access to over 50 sales representatives in 21 US states

Pressure BioSciences Inc (OTCQB:PBIO), which is merging with Cannaworx Inc and SkinScience Labs Inc to become Availa Bio, announced Tuesday that Cannaworx is expanding its sales and distribution network by signing a letter of intent to acquire Louisiana-based Five Leaf Labs (FLL).

The company said the expansion comes at a “critical time” for Cannaworx as it is gearing up for the market launch of its first two products over the coming few weeks.

In a statement, Five Leaf Labs founder and president Keyon Janani said the company’s hemp-derived, CBD products are made exclusively from organic, pesticide-free hemp.

READ: Pressure Biosciences to launch hand sanitizer after rebranding to Availa Bio in triple merger

“All existing and pipeline products are focused entirely on the medicinal properties of CBD. We recently released our first set of CBD-infused products to the US market, which were greeted with excellent, widespread acceptance,” Janani added.

“We attribute the success of our initial launch to both the high quality of our hemp source supply and processing methods, and to the effectiveness of our well-trained, knowledgeable and experienced network of over 50 sales representatives spanning 21 states."

The company said Cannaworx and its principals have a lot riding on 12 products that are being readied for a launch during “the coming year.” These include two products that channel the company's patented/patent pending, full and partial spectrum, hemp-derived phytocannabinoid formulations for pain relief. Cannaworx plans to launch these two products "in the coming months" with a pain indication allowed under "an FDA OTC monograph." 

Meanwhile, Bobby Ghalili, who is the co-founder and president of Cannaworx, said the company was “thoroughly impressed” with Keynon and the FLL team, as well as the company's product line and sales network.

“We are also motivated by the compelling standards of quality that drive Keyon and his team. For example, every product batch at FLL goes through rigorous third-party review and certification for content, consistency, and potency, from one of the most respected academic institutions in the US,” said Ghalili. “We are pleased to be adding Five Leaf Laboratories to the Cannaworx family." 

The combined Avaiia Bio business has an intellectual property estate of 31 issued and a dozen or more pending patents, as well as an existing global base of hundreds of corporate and thousands of retail customers.

The letters of intent between Cannaworx and SkinScience and between Pressure Bio and Cannaworx for the merger are subject to certain closing conditions, the company said.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive

Quick facts: Pressure BioSciences, Inc.

Price: 2.3 USD

Market: OTCQB
Market Cap: $8.94 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pressure BioSciences, Inc. named herein, including the promotion by the Company of Pressure BioSciences, Inc. in any Content on the Site, the...


Full interview: Pressure BioSciences PCT instrument deemed ‘essential’ by...

Pressure BioSciences Inc (OTCMKTS:PBIO) CEO Ric Schumacher tells Proactive the Massachusetts-based company’s patented pressure cycling technology (PCT) was featured in a presentation at the Annual Meeting of the Gynecologic Cancer Society in Brazil.  Schumacher explains the company’s PCT...

on 10/04/2019

3 min read